Research Grants – Translational Research Program

Primary Immunodeficiencies occur when components of the immune system are missing or do not function properly, causing hyper-susceptibility to infection and in some cases severe autoimmunity, IBD, and respiratory diseases. Over the past decade, identification and diagnosis of Primary Immunodeficiency has greatly expanded, and knowledge of causative genes continues to rapidly grow. To date, there are over 450 specific genetic defects identified, which has not only helped advance new therapies but has also been instrumental in advancing our understanding of immunology. It is estimated that as many as 10 million people, if not more, are living with Primary Immunodeficiency worldwide. As such, the time is crucial to support research that will bridge basic science discoveries to the development of clinical applications that will impact overall health outcomes. Advancing research that enhances our understanding of the immune system represents one of the single greatest strategies that biomedical science has to offer to identify new therapies and will greatly benefit those with Primary Immunodeficiencies and the millions that remain undiagnosed.

Purpose:

• To support innovative and novel investigations in Primary Immunodeficiency, focusing on translational research leading to meaningful clinical application.
• To advance the growing knowledge of genotype-phenotype correlations and gain a better understanding of the underlying mechanisms of immune function and dysfunction.
• To support research that will lead to advancement in clinical recognition, diagnostic tools, and innovative therapies that will impact overall health outcomes and improve the quality of life of those affected by Primary Immunodeficiency.
• Grants with the following focus will be strongly considered for awards:
  • Novel Primary Immunodeficiency defects
  • Innovative approaches to in early diagnosis
  • Novel therapeutic strategies
  • Translational impact on patient health (i.e. how a patient will benefit)
  • Reach of the proposed project (i.e. how many patients might benefit)

Letter of intent due March 15